Diabetes, oxidative stress, and antioxidants: A review

Journal of Biochemical and Molecular Toxicology

Volumn 17, Issue 1, 2003, Pages 24-38

  Maritim, A C ^a   Sanders, R A ^b   Watkins III, J B ^b  

^a MOI UNIVERSITY   (Kenya)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidants; Catalase; Glutathione peroxidase; Oxidative stress; Type 1 diabetes mellitus

Indexed keywords

ALLOXAN; AMINOGUANIDINE; ANTIDIABETIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; BOLDINE; CAPTOPRIL; CATALASE; ENALAPRIL; FREE RADICAL; GEMFIBROZIL; GLUCOSE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLYCOSYLATED PROTEIN; INSULIN; ISOEUGENOL; LIPID; MELATONIN; NITECAPONE; NITRITE; NITROPRUSSIDE SODIUM; PIPERINE; PRASTERONE; PROBUCOL; STREPTOZOCIN; SUPEROXIDE DISMUTASE; UBIDECARENONE; UNINDEXED DRUG; VITAMIN;

ANIMAL TISSUE; CELL DAMAGE; CELL ORGANELLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG MECHANISM; ENZYME DENATURATION; GLUCOSE OXIDATION; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPID PEROXIDATION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; RAT; REVIEW;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; FREE RADICALS; OXIDATIVE STRESS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TISSUE DISTRIBUTION;

EID: 0037253073     PISSN: 10956670     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbt.10058     Document Type: Review

References (112)

1. Kataoka S, Satoh J, Fujiya H, Toyota T, Suzuki R, Itoh K, Kumagai K. Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity. Diabetes 1983;32(3):247-253.
2. Like AA, Rossini AA, Guberski DL, Appel MC, Williams RM. Spontaneous diabetes mellitus: Reversal and prevention in the BB/W rat with antiserum to rat lymphocytes. Science 1979;206(4425):1421-1423.
3. Paik SG, Blue ML, Fleischer N, Shin S. Diabetes susceptibility of BALB/cBOM mice treated with streptozotocin. Inhibition by lethal irradiation and restoration by splenic lymphocytes. Diabetes 1982;31(9):808-815.
4. Sandler S, Andersson AK, Barbu A, Hellerstrom C, Holstad M, Karlsson E, Sandberg JO, Strandell E, Saldeen J, Sternesjo J, Tillmar L, Eizirik DL, Flodstrom M, Welsh N. Novel experimental strategies to prevent the development of type 1 diabetes mellitus. Ups J Med Sci 2000;105(2):17-34.
5. Shewade Y, Tirth S, Bhonde RR. Pancreatic islet-cell viability, functionality and oxidative status remain unaffected at pharmacological concentrations of commonly used antibiotics in vitro. J Biosci 2001;26(3):349-355.
6. Ceriello A. Oxidative stress and glycemic regulation. Metabolism 2000;49(2, Suppl 1):27-29.
7. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes 1999;48:1-9.
8. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
9. Chang KC, Chung SY, Chong WS, Suh JS, Kim SH, Noh HK, Seong BW, Ko HJ, Chun KW. Possible superoxide radical-induced alteration of vascular reactivity in aortas from streptozotocin-treated rats. J Pharmacol Exp Ther 1993;266(2):992-1000.
10. Young IS, Tate S, Lightbody JH, McMaster D, Trimble ER. The effects of desferrioxamine and ascorbate on oxidative stress in the streptozotocin diabetic rat. Free Radic Biol Med 1995;18(5):833-840.
11. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: An overview. Meth Enzymol 1990;186:1-85.
12. Saxena AK, Srivastava P, Kale RK, Baquer NZ. Impaired antioxidant status in diabetic rat liver. Effect of vanadate. Biochem Pharmacol 1993;45(3):539-542.
13. McLennan SV, Heffernan S, Wright L, Rae C, Fisher E, Yue DK, Turtle JR. Changes in hepatic glutathione metabolism in diabetes. Diabetes 1991;40(3):344-348.
14. Jiang ZY, Woollard AC, Wolff SP. Hydrogen peroxide production during experimental protein glycation. FEBS Lett 1990;268(1):69-71.
15. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 1987;245(1):243-250.
16. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 1993;334(2):170-174.
17. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994;43(8):1010-1014.
18. Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 1994;94(2):771-778.
19. Hori O, Yan SD, Ogawa S, Kuwabara K, Matsumoto M, Stern D, Schmidt AM. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrol Dial Transplant 1996;11(Suppl 5):13-16.
20. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990;173(3):932-939.
21. McCarthy AD, Etcheverry SB, Cortizo AM. Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: Role in osteoblast development. Acta Diabetol 2001;38(3):113-122.
22. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997;46(Suppl 2):S19-S25.
23. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan SD, Brett J, et al. Advanced glycation end products(AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 1994;91(16):7742-7746.
24. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP. The role of oxidative stress and NF-κB activation in late diabetic complications. Biofactors 1999;10(2/3):157-167.
25. Kador PF, Kinoshita JH. Diabetic and galactosaemic cataracts. Ciba Found Symp 1984;106:110-131.
26. Greene DA, Sima AA, Stevens MJ, Feldman EL, Lattimer SA. Complications: Neuropathy, pathogenetic considerations. Diabetes Care 1992;15(12):1902-1925.
27. Obrosova I, Faller A, Burgan J, Ostrow E, Williamson JR. Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats: Effect of an aldose reductase inhibitor. Curr Eye Res 1997;16(1):34-43.
28. Gonzalez AM, Sochor M, Hothersall JS, McLean P. Effect of aldose reductase inhibitor (sorbinil) on integration of polyol pathway, pentose phosphate pathway, and glycolytic route in diabetic rat lens. Diabetes 1986;35(11):1200-1205.
29. Cheng HM, Gonzalez RG. The effect of high glucose and oxidative stress on lens metabolism, aldose reductase, and senile cataractogenesis. Metabolism 1986;35(4, Suppl 1):10-14.
30. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, Tilton RG. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993;42(6):801-813.
31. Yano M, Matsuda S, Bando Y, Shima K. Lens protein glycation and the subsequent degree of opacity in streptozotocin-diabetic rats. Diabetes Res Clin Pract 1989;7(4):259-262.
32. Ramalho JS, Marques C, Pereira PC, Mota MC. Role of glycation in human lens protein structure change. Eur J Ophthalmol 1996;6(2):155-161.
33. Mizisin AP, Bache M, DiStefano PS, Acheson A, Lindsay RM, Calcutt NA. BDNF attenuates functional and structural disorders in nerves of galactose-fed rats. J Neuropathol Exp Neurol 1997;56(12):1290-1301.
34. Delcroix JD, Michael GJ, Priestley JV, Tomlinson DR, Fernyhough P. Effect of nerve growth factor treatment on p75NTR gene expression in lumbar dorsal root ganglia of streptozocin-induced diabetic rats. Diabetes 1998;47(11):1779-1785.
35. Hounsom L, Horrobin DF, Tritschler H, Corder R, Tomlinson DR. A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia 1998;41(7):839-843.
36. Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA. Effects of DL-α-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000;49(6):1006-1015.
37. Ralevic V, Belai A, Burnstock G. Effects of streptozotocin-diabetes on sympathetic nerve, endothelial and smooth muscle function in the rat mesenteric arterial bed. Eur J Pharmacol 1995;286(2):193-199.
38. Kamei J, Ohsawa M. Effects of diabetes on methamphetamine-induced place preference in mice. Eur J Pharmacol 1996;318(2/3):251-256.
39. Mizisin AP, Kalichman MW, Bache M, Dines KC, DiStefano PS. NT-3 attenuates functional and structural disorders in sensory nerves of galactose-fed rats. J Neuropathol Exp Neurol 1998;57(9):803-813.
40. Kalichman MW, Powell HC, Mizisin AP. Reactive, degenerative, and proliferative Schwann cell responses in experimental galactose and human diabetic neuropathy. Acta Neuropathol (Berl) 1998;95(1):47-56.
41. Chokroverty S, Seiden D, Navidad P, Cody R. Distal axonopathy in streptozotocin diabetes in rats. Experientia 1988;44(5):444-446.
42. Fernyhough P, Gallagher A, Averill SA, Priestley JV, Hounsom L, Patel J, Tomlinson DR. Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy. Diabetes 1999;48(4):881-889.
43. Feher J, Cosmos G, Vereckei A. Free Radical Reactions in Medicine. Berlin: Springer-Verlag; 1987.
44. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc Res 2000;47(3):457-464.
45. Abdel-Wahab MH, Abd-Allah AR. Possible protective effect of melatonin and/or desferrioxamine against streptozotocin-induced hyperglycaemia in mice. Pharmacol Res 2000;41(5):533-537.
46. Chow CK. Vitamin E and oxidative stress. Free Radic Biol Med 1991;11(2):215-232.
47. Asayama K, Hayashibe H, Dobashi K, Niitsu T, Miyao A, Kato K. Antioxidant enzyme status and lipid peroxidation in various tissues of diabetic and starved rats. Diabetes Res 1989;12(2):85-91.
48. Oberley LW. Free radicals and diabetes. Free Radic Biol Med 1988;5:113-124.
49. Pierrefiche G, Topall G, Courboin G, Henriet I, Laborit H. Antioxidant activity of melatonin in mice. Res Commun Chem Pathol Pharmacol 1993;80(2):211-223.
50. Thompson KH, McNeill JH. Effect of vanadyl sulfate feeding on susceptibility to peroxidative change in diabetic rats. Res Commun Chem Pathol Pharmacol 1993;80(2):187-200.
51. Kaul N, Siveski-Iliskovic N, Thomas TP, Hill M, Khaper N, Singal PK. Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition 1995;11(Suppl 5):551-554.
52. Kaul N, Siveski-Iliskovic N, Hill M, Khaper N, Seneviratne C, Singal PK. Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. Molec Cell Biochem 1996;160/161:283-288.
53. Ozansoy G, Akin B, Aktan F, Karasu C. Short-term gemfibrozil treatment reverses lipid profile and peroxidation but does not alter blood glucose and tissue antioxidant enzymes in chronically diabetic rats. Molec Cell Biochem 2001;216:59-63.
54. 10 treatment on antioxidant pathways in normal and streptozotocin-induced diabetic rats. J Biochem Mol Tox 2001;15:41-46.
55. Rauscher FM, Sanders RA, Watkins JB III. Effects of isoeugenol on oxidative stress pathways in normal and streptozotocin-induced diabetic rats. J Biochem Mol Tox 2001;15:159-164.
56. Rauscher FM, Sanders RA, Watkins JB III. Effects of new antioxidant compounds PNU-104067F and PNU-74389G on antioxidant defense in normal and diabetic rats. J Biochem Mol Tox 2000;14:189-194.
57. Rauscher FM, Sanders RA, Watkins JB III. Effects of piperine on antioxidant pathways in tissues from normal and streptozotocin-induced diabetic rats. J Biochem Mol Tox 2000;14:329-334.
58. Maritim AC, Moore BH, Sanders RA, Watkins JB III. Effects of melatonin on oxidative stress in streptozotocin-induced diabetic rats. Int J Toxicol 1999;18:161-166.
59. Aragno M, Tamagno E, Gatto V, Brignardello E, Parola S, Danni O, Boccuzzi G. Dehydroepiandrosterone protects tissues of streptozotocin-treated rats against oxidative stress. Free Radic Biol Med 1999;26(11/12):1467-1474.
60. Cinar MG, Ulker S, Alper G, Evinc A. Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats. Pharmacology 2001;62(1):56-64.
61. Melo SS, Arantes MR, Meirelles MS, Jordao AA Jr, Vannucchi H. Lipid peroxidation in nicotinamide-deficient and nicotinamide-supplemented rats with streptozotocin-induced diabetes. Acta Diabetol 2000;37(1):33-39.
62. Jang YY, Song JH, Shin YK, Han ES, Lee CS. Protective effect of boldine on oxidative mitochondrial damage in streptozotocin-induced diabetic rats. Pharmacol Res 2000;42(4):361-371.
63. Montilla PL, Vargas JF, Tunez IF, Munoz de Agueda MC, Valdelvira ME, Cabrera ES. Oxidative stress in diabetic rats induced by streptozotocin: Protective effects of melatonin. J Pineal Res 1998;25(2):94-100.
64. El-Missiry MA, El Gindy AM. Amelioration of alloxan induced diabetes mellitus and oxidative stress in rats by oil of Eruca sativa seeds. Ann Nutr Metab 2000;44(3):97-100.
65. Kedziora-Kornatowska KZ, Luciak M, Paszkowski J. Lipid peroxidation and activities of antioxidant enzymes in the diabetic kidney: Effect of treatment with angiotensin convertase inhibitors. IUBMB Life 2000;49:303-307.
66. Lal MA, Korner A, Matsuo Y, Zelenin S, Cheng SX, Jaremko G, DiBona GF, Eklof AC, Aperia A. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Diabetes 2000;49:1381-1389.
67. Mohan IK, Das UN. Effect of L-arginine-nitric oxide system on chemical-induced diabetes mellitus. Free Radic Biol Med 1998;25:757-765.
68. El-Khatib AS, Moustafa AM, Abdel-Aziz AA, Al-Shabanah OA, El-Kashef HA. Effects of aminoguanidine and desferrioxamine on some vascular and biochemical changes associated with streptozotocin-induced hyperglycaemia in rats. Pharmacol Res 2001;43(3):233-240.
69. Kedziora-Kornatowska KZ, Luciak M, Blaszczyk J, Pawlak W. Effect of aminoguanidine on erythrocyte lipid peroxidation and activities of antioxidant enzymes in experimental diabetes. Clin Chem Lab Med 1998;36:771-775.
70. Obrosova IG, Stevens MJ. Effect of dietary taurine supplementation on GSH and NAD(P)-redox status, lipid peroxidation, and energy metabolism in diabetic precataractous lens. Invest Ophthalm Vis Sci 1999;40(3):680-688.
71. Obrosova IG, Fathallah L, Greene DA. Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: Effect of DL-α-lipoic acid. Eur J Pharmacol 2000;398:139-146.
72. van Dam PS, van Asbeck BS, Van Oirschot JF, Biessels GJ, Hamers FP, Marx JJ. Glutathione and α-lipoate in diabetic rats: Nerve function, blood flow and oxidative state. Eur J Clin Invest 2001;31(5):417-424.
73. Sailaja Devi MM, Suresh Y, Das. Preservation of the antioxidant status in chemically-induced diabetes mellitus by melatonin. J Pineal Res 2000;29(2):108-115.
74. Caballero F, Gerez E, Battle A, Vazquez E. Preventive aspirin treatment of streptozotocin induced diabetes: Blockage of oxidative status and revertion of heme enzymes inhibition. Chem Biol Interact 2000;126(3):215-225.
75. Sanders RA, Rauscher FM, Watkins JB III. Effects of quercetin on antioxidant defense in streptozotocin-induced diabetic rats. J Biochem Mol Tox 2001;15:143-149.
76. Obrosova IG, Fathallah L, Lang HJ, Greene DA. Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: A prevention study. Diabetologia 1999;42(10):1187-1194.
77. Kocak G, Aktan F, Canbolat O, Ozogul C, Elbeg S, Yildizoglu-Ari N, Karasu C. α-Lipoic acid treatment ameliorates metabolic parameters, blood pressure, vascular reactivity and morphology of vessels already damaged by streptozotocin-diabetes. Diab Nutr Metab 2000;13:308-318.
78. Mekinova D, Chorvathova V, Volkovova K, Staruchova M, Grancicova E, Klvanova J, Ondreicka R. Effect of intake of exogenous vitamins C, E and β-carotene on the antioxidative status in kidneys of rats with streptozotocin-induced diabetes. Nahrung 1995;39:257-261.
79. Altavilla D, Saitta A, Cucinotta D, Galeano M, Deodato B, Colonna M, Torre V, Russo G, Sardella A, Urna G, Campo GM, Cavallari V, Squadrito G, Squadrito F. Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. Diabetes 2001;50(3):667-674.
80. Kim SS, Gallaher DD, Csallany AS. Vitamin E and probucol reduce urinary lipophilic aldehydes and renal enlargement in streptozotocin-induced diabetic rats. Lipids 2000;35(11):1225-1237.
81. Ford I, Cotter MA, Cameron NE, Greaves M. The effects of treatment with α-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat. Metab Clin Exper 2001;50:868-875.
82. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983;52:711-760.
83. Josephy PD. Molecular Toxicology. New York: Oxford University Press; 1997.
84. Gregus Z, Fekete T, Halaszi E, Klaassen CD. Lipoic acid impairs glycine conjugation of benzoic acid and renal excretion of benzoylglycine. Drug Metab Disp 1996;24:682-688.
85. Borenshtein D, Ofri R, Werman M, Stark A, Tritschler HJ, Moeller W, Madar Z. Cataract development in diabetic sand rats treated with α-lipoic acid and its γ-linolenic acid conjugate. Diab Metab Res Rev 2001;17:44-50.
86. Sies H. Damage to plasmid DNA by singlet oxygen and its protection. Mut Res 1993;299:183-191.
87. Santini SA, Marra G, Giardina B, Cotroneo P, Mordente A, Martorana GE, Manto A, Ghirlanda G. Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 1997;46:1853-1858.
88. Winterbourn CC. Superoxide as an intracellular radical sink. Free Radic Biol Med 1993;14:85-90.
89. Stefek M, Sotnikova R, Okruhlicova L, Volkovova K, Kucharska J, Gajdosik A, Gajdosikova A, Mihalova D, Hozova R, Tribulova N, Gvozdjakova A. Effect of dietary supplementation with the pyridoindole antioxidant stobadine on antioxidant state and ultrastructure of diabetic rat myocardium. Acta Diabetologica 2000;37(3):111-117.
90. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 2000;7(6):444-458.
91. Weber P, Bendich A, Machlin LJ. Vitamin E and human health: Rationale for determining recommended intake levels. Nutrition 1997;13(5):450-460.
92. Martinoli L, Di Felice M, Seghieri G, Ciuti M, De Giorgio LA, Fazzini A, Gori R, Anichini R, Franconi F. Plasma retinol and alpha-tocopherol concentrations in insulin-dependent diabetes mellitus: Their relationship to microvascular complications. Int J Vitam Nutr Res 1993;63(2):87-92.
93. Asayama K, Nakane T, Uchida N, Hayashibe H, Dobashi K, Nakazawa S. Serum antioxidant status in streptozotocin-induced diabetic rat. Horm Metab Res 1994;26(7):313-315.
94. Garg MC, Singh KP, Bansal DD. Effect of vitamin E supplementation on antioxidant status of diabetic rats. Med Sci Res 1996;24:325-326.
95. Palmer AM, Thomas CR, Gopaul N, Dhir S, Anggard EE, Poston L, Tribe RM. Dietary antioxidant supplementation reduces lipid peroxidation but impairs vascular function in small mesenteric arteries of the streptozotocin-diabetic rat. Diabetologia 1998;41(2):148-156.
96. Komers R, Oyama TT, Chapman JG, Allison KM, Anderson S. Effects of systemic inhibition of neuronal nitric oxide synthase in diabetic rats. Hypertension 2000;35(2):655-661.
97. Kowluru RA, Engerman RL, Kern TS. Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine. Curr Eye Res 2000;21(4):814-819.
98. Hunt JV, Dean RT, Wolff SP. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J 1988;256(1):205-212.
99. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991;10:339-352.
100. Baynes JW, Thorpe SR, Murtiashaw MH. Nonenzymatic glucosylation of lysine residues in albumin. Methods Enzymol 1984;106:88-98.
101. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414(6865):813-820.
102. Munch G, Thome J, Foley P, Schinzel R, Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Brain Res Rev 1997;23(1/2):134-143.
103. Brownlee M. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic complications. In: Rifkin H, Porte Jr D, editors. Diabetes Mellitus: Theory and Practice. New York: Elsevier; 1990. pp 279-291.
104. Chakravarthy BR, Wang J, Tremblay R, Atkinson TG, Wang F, Li H, Buchan AM, Durkin JP. Comparison of the changes in protein kinase C induced by glutamate in primary cortical neurons and by in vivo cerebral ischaemia. Cell Signal 1998;10(4):291-295.
105. Aruna RV, Ramesh B, Kartha VN. Effect of betacarotene on protein glycosylation in alloxan induced diabetic rats. Indian J Exp Biol 1999;37(4):399-401.
106. Vallejo S, Angulo J, Pieiro C, Cercas E, Sanchez-Ferrer A, Nevado J, Llergo JL, Rodriguez-Manas L, Sanchez-Ferrer CF. Treatment with acarbose may improve endothelial dysfunction in streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol 2000;36:255-262.
107. Kador PF, Lee JW, Fujisawa S, Blessing K, Lou MF. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats. J Ocul Pharm Therap 2000;16(2):149-160.
108. Watkins JB III, Klaunig JE, Smith HM, Cornwell P, Sanders RA. Streptozotocin-induced diabetes increases γ-glutamyltranspeptidase activity but not expression in rat liver. J Biochem Mol Toxicol 1998;12(4):219-225.
109. Lu SC, Kuhlenkamp J, Wu H, Sun WM, Stone L, Kaplowitz N. Progressive defect in biliary GSH secretion in streptozotocin-induced diabetic rats. Am J Physiol 1997;272(2, Pt 1):G374-G382.
110. Hemmings SJ, Pekush RD. The impact of type I diabetes on rat liver γ-glutamyltranspeptidase. Molec Cell Biochem 1994;139(2):131-140.
111. Watkins JB III, Sanders RA. Diabetes mellitus-induced alterations of hepatobiliary function. Pharmacol Rev 1995;47(1):1-23.
112. Cornwell PD, Watkins JB III. Changes in the kinetic parameters of hepatic gamma-glutamyltransferase from streptozotocin-induced diabetic rats. Biochim Biophys Acta 2001;1545(1/2):184-191.